300 related articles for article (PubMed ID: 27598329)
1. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
2. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
3. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
4. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
6. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
7. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
8. CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.
Melo RCC; Longhini AL; Bigarella CL; Baratti MO; Traina F; Favaro P; de Melo Campos P; Saad ST
PLoS One; 2014; 9(1):e85926. PubMed ID: 24497931
[TBL] [Abstract][Full Text] [Related]
9. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
10. CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells.
Melo RCC; Ferro KPV; Duarte ADSS; Olalla Saad ST
Stem Cell Res Ther; 2018 Feb; 9(1):34. PubMed ID: 29433559
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
12. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
14. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
[TBL] [Abstract][Full Text] [Related]
15. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
17. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
[TBL] [Abstract][Full Text] [Related]
18. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
Mehrpouri M
Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.
Werner L; Guzner-Gur H; Dotan I
Theranostics; 2013; 3(1):40-6. PubMed ID: 23382785
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
